Medication Monitor



Generic Name (Trade Name—Company)
Notes
March 13, 2018

Cinacalcet hydrochloride

(Sensipar—[Amgen] Aurobindo, Cipla)
FDA approves two first generics of Sensipar

FDA has approved the first generics of Amgen’s Sensipar, marketed by Aurobindo and Cipla.

The cinacalcet hydrochloride tablets are indicated for treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis, hypercalcemia in adult patients with parathyroid carcinoma (PC), and severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.

Both generics will be available in 30-, 60- and 90-mg dosage strengths.